Print this page
-
Analysis of Circulating Lymphoid Cells in Patients With (or Treated For) Non-Hodgkin's Lymphoma
Protocol: 011811Principal Investigator:
- Roger Strair M.D., Ph.D. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
R1979-HM-1333: An Open-label, Multi-center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 bispecific Monoclonal Antibody, in Patients with CD20+ B-cell Malignancies Previously Treated with CD20 Directed Antibody Therapy.
Protocol: 011411Principal Investigator:
- Rajat Bannerji Dr. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia
Non-Hodgkin's Lymphoma -
COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Protocol: 111502Principal Investigator:
- Richard Drachtman M.D. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia -
E4412: A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Protocol: 011505Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Hodgkin's Lymphoma -
AALL1521/Incyte 18424-269: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High Risk CRLF-2 Rearranged and or JAK Pathway-Mutant Acute Lymphoblastic Leukemia.
Protocol: 111603Principal Investigator:
- Richard Drachtman M.D. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
AAML1531: Risk-Stratified Therapy for Acute Myeloid Leukemima in Down Syndrome.
Protocol: 111602Principal Investigator:
- Richard Drachtman M.D. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, not otherwise specified
Any Site
